Forget Pot Stocks…EVAHF back on High Alert as it spearheads the Once-in-a-Lifetime SHROOM BOOM!

EGF THERAMED HEALTH CORP.

USA: EVAHF  |  Canada: TMED  |  Germany: AUHP
Last Price: .18  |  Website  |  SEC Filings  |  Latest News

Over the last decade, there is no doubt that the single biggest BOOM Sector has been Cannabis.

And while the Boom is far from over….it has certainly matured – creating a paradigm shift in the markets and generating fortunes for those who got in early or at the right time.

You see, forward-thinking and industrious investors are always looking for the “Next Big Thing”.

What will be the successor to Cannabis once it’s legal nationwide??

WELL THE NEXT BIG THING ON WALL STREET
IS FINALLY HERE!!

[fname], if you missed this alert last time, prepare yourself for the SHROOM BOOM!

Yes, believe it or not…Wall Street is going gaga about the prospect of Medicinal Mushrooms!!!

I didn’t believe it at first, so I actually contacted a few big wigs on the Street to confirm this. Large investor dollars are pouring into this space!

Psilocybin is the active compound in what i known as a magic mushrooms or a psychedelic mushroom. It is said to be the key to treating certain forms of depression and potentially other mental issues such as anxiety, addiction, and even Alzheimer’s Disease.

There’s a reason why John Hopkins has a $17M research center just for psychedelic research.

There’s also a reason why Shark Tank investor Kevin O’ Leary was part of the investment round for a psychedelic pharmaceutical company MindMed.

So without a doubt, Psychedelic Stocks are gaining global media attention and Today’s New Alert is truly at the forefront of what many are calling, the “SHROOM BOOM”!

WE ARE ISSUING A NEW ALERT ON EVAHF!

The last time we covered this exciting and groundbreaking company, EVAHF’s stock crushed all resistance, delivering up to 74% GAINS in just ONE day!

EGF Theramed (EVAHF) is a consumer technology company that has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations.

On May 6, the company took a bold first step with the announcement of it’s 30% Purchase of Pharmadelic Labs – becoming among the FIRST publicly-traded companies to enter this exciting new space!!

THINK ABOUT THIS…

Imagine you had shares of the FIRST Cannabis Stock when it first hit the markets – Canopy Growth (then known as Tweed Inc).  You’d have turned a simple $1000. into over $21,000!!

EVAHF’s Pharmadelic Labs is not working to create drugs that require FDA approval and could take tens of years for approval.

INSTEAD…they are working to patent and create intellectual property that can mass produce high-grade psilocybin for implementation in legal jurisdictions in a number of days versus weeks!

And consider the UPSIDE here….

This is a Stock that was trading at highs of $18/share last May!! (on a post-consolidated basis)

Now trading at historical support levels where it has rallied from in the past + a Bottomed Chart near 52-Week Lows and a descending wedge pattern near it’s apex, EVAHF may have more upside potential than ever before!!

chart

Not to mention it’s got an incredibly Low Float which means we could have a runner on our hands with BREAKOUT off support.

So are you coming along on this “trip”? 😉   Let’s dig in….

EVAHF – AT THE FOREFRONT OF THE SHROOM REVOLUTION!
With Psychedelic drugs gathering support as a bona fide treatment for mental health problems, EVAHF’s recent acquisition of a 30% equity interest in Pharmadelic Labs Corp. positions this pioneering company at the frontier of medical science.

At the heart of it all is Psilocybin.  But what is it?

shroomsPsilocybin is a psychoactive substance found in around 200 species of mushroom.

Much of the science remains surrounding the molecule remains unexplored, but it has been theorized that psilocybin works with the body’s serotonin system to heighten emotional responses, which helps to actively confront mental health issues such as depression.

Psilocybin was designated Schedule I in the 1970 Criminal Substances Act, making it a drug with “no currently accepted medical use and a high potential for abuse”.

However, this was largely a politically motivated decision made to oppose the 1960’s hippie counterculture.

In truth, Magic mushrooms in fact are the safest “recreational” drug to take and those who take them are the most sensible and well prepared, according to the 2017 Global Drug Survey.

Last May, residents of Denver, Colorado voted to Decriminalize the drug, and Oakland, California’s city council unanimously concluded that consuming numerous psychedelic plants, mushrooms included, should not be considered criminal.

This year Santa Cruz become the latest city to decriminalize “magic mushrooms” and other natural psychedelics, including ayahuasca and peyote.

Like Cannabis, the movement to decriminalize is picking up steam across the U.S. — so this could just be getting started!!

So what is Pharmadelic Labs and how do they plan to generate huge profits in the Psilocybin/Psychedelic space?  Read on…

This may get a bit “sciencey” but here goes…

EVAHF’s Pharmadelic Labs is a biotech company focusing on improving and patenting engineering processes for the biosynthesis of compounds – primarily psilocybin, the psychoactive component of magic mushrooms.

The company has begun to research psilocybin and psychedelics biosynthesis.

So what does that mean?  By implanting its DNA in yeast, the company is creating a commercially viable process to derive psilocybin from yeast.

The main advantages of this method are threefold:
📍 it is significantly quicker than growing and then extracting from mushrooms (days rather than weeks)
📍 The technology can theoretically produce a controlled and uniform level of psilocybin throughout the finished product
📍 much cheaper to produce on a mass scale than greenhouse growing.

This has great potential for application in many industries, including the Pharmaceuticals industry!

Pharmadelic Labs’ biosynthesis process is clean and economical, and much quicker than cultivating mushrooms by themselves – approximately 3 days rather than up to 10 weeks!

The company will also be providing an effective alternative to chemical synthesis. Chemical synthesis of psilocybin costs upwards of $7,000 per gram, which is far more expensive than the company’s methods.

SO HOW DOES BIOSYNTHESIS OF PSILOCYBIN WORK?

Step 1:  Order synthetic DNA from hallucinogenic mushrooms

Step 2:  Install DNA into genome of industrial brewing yeast

Step 3:  Cultivate yeast on a large scale

Step 4:  Extract psilocybin

Step 5:  Create pharmaceutical product

EVAHF’s Pharmadelic Labs aims to develop a portfolio of intellectual property around biosynthesis pathways using yeast and psilocybin. The company will be working with a wide range of partners across multiple industries, and potentially pharmaceutical companies creating products for the nascent psychedelics market in the future.

STILL NOT CONVINCED? READ THIS…

Whether you like it or not, the race for billions in profit has begun as the Psychedelic sector opens up!  But everyone will need an edge over their competition.

This edge here with EVAHF is not in the drug itself or the molecule, or the compound, but in the process and the way the compound is mass produced in a lab environment.

And this is where EVHAF-owned Pharmadelic Labs comes into the equation with a potential solution for this exciting and emerging mushroom space needed to gain that edge over their competition

Also consider the Tremendous Revenue Potential of the Mental Health Market…

Mental health is increasingly recognized as one of the biggest medical issues in the world. This costs countries both directly, through medication and hospitalization, and indirectly, through productivity losses.

🔹 According to the Centers for Disease Control, suicide was the 10th leading cause of death in the US in 2017.

🔹 Healthypeople.gov has found that in any given year, over 18% of US adults suffer from mental illness.

🔹 Forbes has reported that mental illness costs the U.S. economy nearly $200 billion a year.

🔹 According to Brands Essence Research, the global antidepressant drugs market was estimated to be over $13.5 billion in 2018 and is predicted to rise to nearly $16 billion by 2025.


Ongoing clinical trials are discovering the uses of psilocybin in the treatment of addiction and other mental health problems.
Watch the recent 60 Minutes documentary above that explores current efforts to treat harmful mental health issues.

Current treatments such as opioids have potentially harmful side effects such as addictiveness, but psychedelic drugs like psilocybin may avoid these downsides.

An article published by Johns Hopkins University in 2018 recommended that the government downgrade psilocybin’s classification to Schedule IV; a drug with “low potential for abuse and low risk of dependence”.  It has also shown promising results in treating depression, as well as in palliative care.

More studies around psilocybin:

A single dose of the psychedelic ingredient in “magic mushrooms” may bring long-lasting relief to cancer patients who suffer anxiety and depression, a new, small study suggests. (SOURCE)

Doctors Are Turning to Psychedelics to Treat Depression and Addiction (SOURCE)

A Radical Approach to Beating Addiction (SOURCE)

Doctors Are Giving Alzheimer’s Patients LSD (SOURCE)

Researchers from the University of South Florida discover that psilocybin can also bind itself to receptors that stimulate healing. (SOURCE)

IS MEDICAL TOURISM NEXT FOR EVAHF?

You can tell this company is confident about it’s new direction into Psychedelics with it’s most recent acquisition….

EGF Theramed Health Closes Joint Venture with Acquisition of 40% Interest in Biosynthesis and Wellness Company, Green Parrot Labs

EVHAF is essentially doubling down here with Green Parrot – a Caribbean-based company that plans to offer wellness centers and labs for research and development into biosynthesis pathways for psilocybin and cannabinoids.

“The environment of the Caribbean is a huge draw for medical tourism, and we believe that our wellness centers will provide exceptional treatment for those with inflammatory bowel disease.” – Ron McKenna, CEO of Green Parrot

The operations of Green Parrot plan to take advantage of the generous laws in Barbados, Jamaica and the British Virgin Islands towards medical tourism and research into rare compounds. Magic mushrooms grow naturally and may be legally cultivated and consumed in Jamaica and the British Virgin Islands, making the islands an excellent location to conduct research into the compound.

David Bentil, the Company’s previous CEO commented, “The Joint Venture with Green Parrot Labs represents a progression to our platform as we continue to expand our research and development work in the CBD and psilocybin arenas.

Caribbean countries are working hard to provide a conducive working environment in the psychedelic space and their laws make conducting business in this area attractive.”

And since we last covered EVAHF, Green Parrot Labs made another major move, gaining a footprint in Jamaica via an MOU for a medical tourism treatment center, initially for the treatment of irritable bowel disorder.

THE BOTTOM LINE
Look, when I first heard about Psychedelics and magic mushrooms being a “thing” that Wall Street was becoming hot on, I too was shocked.

But the more I read about EVAHF and the all the positive aspects of psilocybin in future treatments, I AM NOW CONVINCED….

THIS WILL BE THE NEXT BOOM SECTOR ON WALL STREET!!

And the prospect of being at the “GROUND FLOOR” of this movement has us salivating at the future gain potential of this sector and EVAHF itself!

So with a Low Float, Massive Upside Potential, a Bottomed Chart, and a groundbreaking business….the time is NOW!

EVAHF could be a play you’ll be bragging about in the decades to come!!!

So if  you missed it last time, make sure you put it on your screen RIGHT NOW and Follow on Twitter for all the Updates + Play-by-Play!

Good Trading,

Xavier Wright
Editor | WallStreetAlerts.org


Still need an Online Broker to place trades? 

TD Ameritrade
TD Ameritrade 0 Commission
Our Analysts HIGHLY recommend TD AMERITRADE,
Where Smart Investors Get Smarter
℠.
*Applies to U.S. exchange-listed stocks, ETFs, and options. A $0.65 per contract fee applies for options trades.

Advertisement

text alerts

.

Home  |  Trading School  |  Twitter  |  ContactUNSUBSCRIBEView in Browser

Disclaimer2

We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.

COMPENSATION: WallStreetAlerts.org has been compensated seventy-five thousand dollars cash via bank wire by a third party, Awareness Consulting Network LLC for a two day marketing services contract. WallStreetAlerts.org does not own any shares of EVAHF. WallStreetAlerts.org has been previously compensated sixty-five thousand dollars cash via bank wire by a third party, Awareness Consulting Network LLC for a two day marketing services contract which has expired. WallStreetAlerts.org does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.  WallStreetAlerts.org has been previously compensated one-hundred and eighty thousand dollars cash via bank wire by Theramed Health Corporation for a one week advertising services contract which has expired.

Disclaimer1